Research and Development

Accelerating genetic discovery through collaborative research

The origins of Haegsim Yobeob are rooted in the pioneering research that has shaped genetic medicine and gene therapy. This has led to us forging strong partnerships with researchers from renowned institutions, bioscience organizations and patient advocacy groups. Consequently, we bring with us a wealth of established technologies, development practices and clinical knowledge to ensure the protection of your discoveries and facilitate their progress into clinical practice.

Our Pipeline

Haegsim Yobeob's latest prospect, GENEX-3 (the first trifold effector gene-drug candidate being assessed for the treatment of heart failure after the examination of the first cohort data), is a non-viral trifold-effector plasmid intended to make a permanent expression of human S100A1, SDF-1a, and VEGF-165 genes possible in order to tackle multiple pathways of heart failure.

Making innovative treatments that provide patients a better future

The Connection to the Scientific Community

Rather than acquiring research programs to add to a pipeline diagram, we prefer to collaborate with those who are eager to actively contribute to the progress of gene therapy technology for the benefit of patients.

  • Detailed analysis using technology resources, data analytics, and scientific partners to identify an effective development course;
  • A valuable addition to your lab that draws on the knowledge of your research teams' scientific fields;
  • Industry-leading gene therapy technologies, procedures, and AAV production capabilities that have been demonstrated;
  • Extensive expertise and a unique clinical translation methodology to reduce risk and improve clinical result predictability.

Our Resolute Approach to Product Development

The goal of Haegsim Yobeob's research is to create novel treatments that can significantly improve patients' lives. Our academic connections with esteemed researchers at top-tier research institutions have given us a solid research basis upon which to build our translational approach to product development. Focused on critical diseases for which there are currently insufficient treatment alternatives is our current pipeline of clinical-stage products.

Our researchers' creative work serves as the foundation for our cell treatment technology. Furthermore, Haegsim Yobeob has an exclusive license agreement with a number of medical centers for intellectual property related to the development of exosomes, a technology that can serve as a next-generation therapeutic platform in regenerative medicine for the treatment and prevention of a wide range of diseases.

At Haegsim Yobeob, ongoing studies are being conducted in the fields of product characterization, extending the usage of existing products, creating products of the next generation, and discovering new technologies.